Analysis of clinical characteristics and outcomes of ALK positive (ALK plus ) patients treated with ALK inhibitors (ALKi).

被引：0
|
作者：
Perez, Susana Cedres
Aranda, Nuria Pardo
Navarro, Alejandro
Marti, Alex Martinez
de Castro, Ana Maria Martinez
Cabrera, Guadalupe
Vilaro, Marta
Carbonell, LLuisa
de la Fuente, Iris
Piera, Adelaida
Martinez, Lidia
Hernandez-Losa, Javier
Sansano, Irene
Felip, Enriqueta
机构：
[1] Vall dHebron Univ Hosp, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Dept Med Oncol, Barcelona, Spain
[3] Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain
[4] Inst Salvadoreno Seguro Social, San Salvador, El Salvador
[5] Vall dHebron Inst Oncol, Oncol Data Sci OdysSey Grp, Barcelona, Spain
[6] Vall dHebron Univ Hosp, Dept Pathol, Barcelona, Spain
[7] Vall dHebron Univ, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.e20550
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e20550
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Diverse Characteristics of ALK plus NSCLC Patients in the United States
    Bendaly, Edmond
    Sasane, Medha
    Zhang, Jie
    Swallow, Elyse
    Macalalad, Alexander R.
    Patel, Dony
    Kageleiry, Andrew
    Galebach, Philip
    Kercheval, Jacquelyn
    Stein, Karen
    Guerin, Annie
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S376
  • [42] A retrospective observational study to evaluate patient-reported outcomes (PROs) in patients with metastatic ALK plus non-small cell lung cancer (NSCLC) treated with ALK inhibitors
    Biber, Josh
    Wan, Yin
    Churchill, Eric N.
    Danes, Christopher G.
    Socinski, Mark A.
    Spira, Alexander I.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E36 - E36
  • [43] Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
    Lin, Jessica J.
    Zhu, Viola W.
    Yoda, Satoshi
    Yeap, Beow Y.
    Schrock, Alexa B.
    Dagogo-Jack, Ibiayi
    Jessop, Nicholas A.
    Jiang, Ginger Y.
    Le, Long P.
    Gowen, Kyle
    Stephens, Philip J.
    Ross, Jeffrey S.
    Ali, Siraj M.
    Miller, Vincent A.
    Johnson, Melissa L.
    Lovly, Christine M.
    Hata, Aaron N.
    Gainor, Justin F.
    Iafrate, Anthony J.
    Shaw, Alice T.
    Ou, Sai-Hong Ignatius
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (12) : 1199 - +
  • [44] Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients
    Haratake, Naoki
    Seto, Takashi
    Takamori, Shinkichi
    Toyozawa, Ryo
    Nosaki, Kaname
    Miura, Naoko
    Ohba, Taro
    Toyokawa, Gouji
    Taguchi, Kenichi
    Yamaguchi, Masafumi
    Shimokawa, Mototsugu
    Takenoyama, Mitsuhiro
    THORACIC CANCER, 2019, 10 (09) : 1779 - 1787
  • [45] Psychiatric symptoms in patients with metastatic ALK-positive NSCLC treated with third-generation ALK-inhibitors: a brief review and case series
    Pagliaro, Arianna
    Rossi, Sabrina
    Santoro, Armando
    Toschi, Luca
    JOURNAL OF MEDICAL SCIENCE, 2024, 93 (03):
  • [46] WHOLE BODY AND INTRACRANIAL EFFICACY OF CERITINIB IN ALK-INHIBITOR (ALKi)-NAIVE PATIENTS WITH ALK-REARRANGED (ALK plus ) NSCLC AND BASELINE BRAIN METASTASES (BM): RESULTS FROM ASCEND-1 AND-3
    Mehra, Ranee
    Felip, Enriqueta
    Tan, Daniel Shao-Weng
    Kim, Dong-Wan
    Orlov, Sergey
    Park, Keunchil
    Yu, Chong-Jen
    Mok, Tony
    Nishio, Makoto
    Scagliotti, Giorgio V.
    Spigel, David R.
    Sutradhar, Santosh
    Cesic, Dajana
    Shaw, Alice Tsang
    NEURO-ONCOLOGY, 2016, 18 : 28 - 29
  • [47] Real-World Characteristics and Outcomes for ALK plus NSCLC in Korea
    Lim, Sung Hee
    Yoh, Kyung Ah
    Lee, Jong-Seok
    Ahn, Myung-Ju
    Kim, Yu Jung
    Kim, Se Hyun
    Zhang, Jie
    Patel, Dony
    Swallow, Elyse
    Kageleiry, Andrew
    Yi, Hwabok
    Stein, Karen
    Degun, Ravi
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S376 - S376
  • [48] ALK Inhibitors in Patients With ALK Fusion-Positive GI Cancers: An International Data Set and a Molecular Case Series
    Ambrosini, Margherita
    Del Re, Marzia
    Manca, Paolo
    Hendifar, Andrew
    Drilon, Alexander
    Harada, Guilherme
    Ree, Anne Hansen
    Klempner, Samuel
    Maelandsmo, Gunhild Mari
    Flatmark, Kjersti
    Russnes, Hege G.
    Cleary, James M.
    Singh, Harshabad
    Sottotetti, Elisa
    Martinetti, Antonia
    Randon, Giovanni
    Sartore-Bianchi, Andrea
    Capone, Iolanda
    Milione, Massimo
    Di Bartolomeo, Maria
    Pietrantonio, Filippo
    JCO PRECISION ONCOLOGY, 2022, 6 (01)
  • [49] Analysis of the Genomic Landscape in ALK plus NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes
    du Tertre, Mathilde Couetoux
    Marques, Maud
    Tremblay, Lise
    Bouchard, Nicole
    Diaconescu, Razvan
    Blais, Normand
    Couture, Christian
    Pelsser, Vincent
    Wang, Hangjun
    Higenell, Valerie
    Izzi, Luisa
    Gambaro, Karen
    Hoffert, Cyrla
    Srivastava, Archana
    Spatz, Alan
    Rousseau, Caroline
    McNamara, Suzan
    Cohen, Victor
    Batist, Gerald
    Agulnik, Jason
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (09) : 1628 - 1636
  • [50] Genotypic Characteristics and Resistance Mutations in Advanced ALK plus NSCLC: The ALK-PATHFINDER Study
    Lopez Castro, R.
    Insa Molla, A.
    Esteban Gonzalez, E.
    Gomez Rueda, A.
    Isla Casado, D.
    Barneto Aranda, I.
    Bayona Anton, C.
    Majem Tarruella, M.
    Peralta Munoz, S.
    Garcia Campelo, R.
    Bosch Barrera, J.
    Juan Vidal, O. J.
    Bernabe Caro, R.
    Vicente Baz, D.
    Gordo Flores, R.
    Carrizo Mijarra, N.
    Ferrer Sanchez, I.
    Lopez Munoz, M. E.
    Ponce Aix, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E13 - E14
12345